Hikal reports Q1 FY26 consolidated loss of Rs. 22.4 Cr
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Athena is also exploring the use of this technology for expanded carrier screening
Vasograin Plus represents a major advancement in the treatment of migraine
The system, called GeneAgent, cross-checks its own initial predictions for accuracy against information from established, expert-curated databases
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
NewCo’s pipeline includes five investigational medicines
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies
Subscribe To Our Newsletter & Stay Updated